
样式: 排序: IF: - GO 导出 标记为已读
-
Issue Information Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-07
Click on the article title to read more.
-
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β0 Thalassemia Major Patient Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-07 Arun Thomas, Kirstin Lund, Viviene Ballon, Barbara J. Bain
A 6-year-old boy of Libyan ethnic origin was referred to pediatric hematology 3 months after entering the United Kingdom as a refugee. The child was known to have thalassemia major. His parents were first cousins. He had previously been transfused every 4 weeks, received chelation therapy and had been splenectomized. More recently, transfusion requirement had increased to every 2 weeks and he had developed
-
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-07 Samuel Yamshon, Jean L. Koff, Melissa C. Larson, Brad S. Kahl, Carla Casulo, Izidore S. Lossos, Sara Haddadi, Michele Stanchina, Dai Chihara, Amy Ayers, Thomas M. Habermann, Yucai Wang, Arushi Khurana, Grzegorz S. Nowakowski, Tanner W. Reicks, Umar Farooq, Brian K. Link, Jonathon B. Cohen, Peter Martin, Jia Li, Ashwini Shewade, Connie Lee Batlevi, Andrea Lo‐Rossi, David Fox, Anthony Masaquel, Yong
-
Multicenter Prospective First-Line Helicobacter Pylori Eradication for Localized Gastric “Pure” Diffuse Large B-Cell Lymphoma Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-06 Li-Tzong Chen, Kun-Huei Yeh, Chung-Wu Lin, Tsang-En Wang, Ming-Chung Wang, Chin-Fu Hsiao, Chieh-Chang Chen, Jyh-Ming Liou, Hsiu-Po Wang, Ming-Feng Wei, Hsiao-Wei Lee, Chia-Tung Shun, Tsang-Wu Liu, Hwei-Fang Tien, Ming-Shiang Wu, Sung-Hsin Kuo, Ann-Lii Cheng
-
Recipient Cells Are the Source of Hematologic Malignancies After Graft Failure and Mixed Chimerism in Adults With SCD Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-06 Mohamed A. E. Ali, Emily M. Limerick, Matthew M. Hsieh, Kalpana Upadhyaya, Xin Xu, Oswald Phang, Jean Pierre Kambala Mukendi, Katherine R. Calvo, Maria Lopez‐Ocasio, Pradeep Dagur, Courtney D. Fitzhugh
Hematopoietic cell transplant (HCT) is the only curative option for individuals with sickle cell disease (SCD). Traditionally, young patients with a human leukocyte antigen (HLA)-matched donor received myeloablative conditioning followed by HCT to completely replace recipient hematopoietic cells with healthy donor cells (full donor chimerism). Unfortunately, less than 15% of patients have an HLA-matched
-
Correction to “Secondary‐Type Mutations Do Not Impact Prognosis in Acute Myelogenous Leukemia AML With Mutated NPM1” Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-05
Wright MF, Pozdnyakova O, Hasserjian RP, et al., 2022. “Secondary-Type Mutations Do Not Impact Prognosis in Acute Myelogenous Leukemia AML With Mutated NPM1.” American Journal of Hematology 97, no. 12: E462–E465. https://doi.org/10.1002/ajh.26730. The title should read: Secondary-type mutations do not impact prognosis in AML with mutated NPM1. The words “acute myelogenous leukemia” should not appear
-
Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin (ATLG) vs. Anti‐Thymocyte Globulin (ATG) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-05 Anne Beatrice Notarantonio, Stéphane Morisset, Romain Piucco, Michaël Pérès, Laura Boulangé, Alizée Alitcher, Jordan Brouard, Lucile Monchablon, Arnaud Campidelli, Siham El Ouahabi, Charles Guisnel, Charline Moulin, Céline Kicki, Gabrielle Roth‐Guepin, Pierre Feugier, Marcelo De Carvalho Bittencourt, Alice Aarnink, Maud D'Aveni‐Piney, Sébastien Hergalant, Simona Pagliuca, Marie Thérèse Rubio
Both anti‐T‐lymphocyte globulin (ATLG‐Grafalon) and anti‐thymocyte globulin (ATG‐Thymoglobulin) prevent acute and chronic graft‐versus‐host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Despite distinct manufacturing and biological characteristics, the two brands of rabbit anti‐lymphocyte globulins have never been compared in a prospective way. In this monocentric
-
2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-04 Debbie Jiang, Michael Wang, Allison P. Wheeler, Stacy E. Croteau
Clinical trial programs for inherited bleeding disorders feature an array of innovative prophylaxis options: engineered clotting factor concentrates, FVIIIa mimetics, gene therapies, and biologics to bolster thrombin generation (rebalancing agents). Increasingly, non‐hemophilia bleeding disorders and a broader demographic (females, children, and infants) are being incorporated into study populations
-
Sharpening the Tools to Get the Edge on Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-04 Shai Shimony, Jacqueline S. Garcia
Conflicts of Interest J. Garcia has received research grants from AbbVie, Newave, Pfizer, and Genentech, and was an advisory board member or on the steering committee for AbbVie, Genentech, and Servier. S. shimony has no conflicts to declare.
-
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1 Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-04 Evan C. Chen, Shai Shimony, Marlise R. Luskin, Richard M. Stone
Mutations in nucleophosmin 1 (NPM1) are diseased‐defining genetic alterations encountered in approximately one‐third of cases of acute myeloid leukemia (AML). A mutation in NPM1 confers a more favorable prognosis; however, clinical outcomes of NPM1–mutated AML (NPM1mut AML) are diverse due to the heterogeneity of disease biology, patient characteristics, and treatment received. Research over the last
-
Balancing the Scales: Optimizing Reporting of Infection Rates in Clinical Trials of Bispecific Antibodies in Multiple Myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-31 Joshua Richter, Madhav V. Dhodapkar, Mengying Li, Mina Awad, Christian Hampp, Kate Knorr, Glenn Kroog, Tito Roccia, Naresh Bumma
Conflicts of Interest J.R. reports consulting or participation in an advisory role for Takeda, Adaptive Biotechnologies, Karyopharm Therapeutics, Antengene, Sanofi, Genentech, Pfizer, Janssen, AbbVie, Bristol Myers Squibb/Celgene, and Regeneron; speakers' bureau engagement for Celgene, Janssen, Bristol Myers Squibb, Sanofi, and Adaptive biotechnologies; and reimbursement for travel, accommodation,
-
Dirt Under the Finger‐Nails—More Malignant Than Malignancy Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-30 Sumeet Mirgh, Sujata Lall, Sachin Punatar, Anant Gokarn, Nishant Jindal, Akanksha Chichra, Vivek Bhat, Navin Khattry
-
Association of Sleep Traits With Venous Thromboembolism: Prospective Cohort and Mendelian Randomization Studies Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-30 Yuqian Li, Feifei Sun, Chao Ji, Honghao Yang, Zheng Ma, Yuhong Zhao, Zhiying Zhao, Yang Xia
Previous research indicates an association between sleep traits and venous thromboembolism (VTE) risk, though causal relationships remain uncertain. This study evaluated combined and independent associations between sleep traits and VTE risk using UK Biobank data and explored the causal associations between sleep traits and VTE through two‐sample Mendelian randomization (MR) analyses. Hazard ratios
-
Non‐Transfusion‐Dependent Thalassemia: An Image Gallery Worth a Thousand Words Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-30 Khaled M. Musallam, Sujit Sheth, Thomas D. Coates, Hanny Al‐Samkari, Maria Domenica Cappellini, Kevin H. M. Kuo, Vip Viprakasit, Ali T. Taher
Our understanding of the molecular pathways and associated clinical presentations characterizing various thalassemia phenotypes has substantially improved over the years. Non-transfusion-dependent thalassemia (NTDT) refers to patients who present with mild–moderate anemia, which does not necessitate lifelong, regular transfusion therapy. This typically includes patients with β-thalassemia intermedia
-
Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-29 Bruno Fattizzo, Carmelo Gurnari, Sabrina Giammarco, Antony Ricchiuti, Hussein Awada, Marta Bortolotti, Nicole Galli, Giacinto Luca Pedone, Francesco Versino, Dario Consonni, Roochi Trikha, Shreyans Gandhi, Simona Sica, Jaroslaw P. Maciejewski, Austin Kulasekararaj, Wilma Barcellini
We retrospectively analyzed a large international cohort of 1113 patients with aplastic anemia to evaluate treatment choice and outcome in elderly patients as compared with a younger population. Overall, 319 (29%) patients were > 60 years old at diagnosis (60–64 years (n = 85), 106 65–69 years (n = 106), and 128 > 70 years (n = 128)). Elderly patients showed a more severe thrombocytopenia at onset
-
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-28 Jiří Mayer, Petra Čičátková, Lenka Kováčová, Marie Jarošová, Michal Karas, Pavel Jindra, Hana Klamová, Kateřina Machová Poláková, Olga Černá, Eduard Cmunt, Petra Bělohlávková, Pavel Žák, Edgar Faber, Tomáš Papajík, Lukáš Stejskal, Ivana Ježíšková, Barbora Weinbergerová, Tomáš Jurček, Tomáš Horňák, Daniela Žáčková, Šárka Ransdorfová, Milena Holzerová, Tomáš Pavlík
-
TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-28 Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G. Loscocco, Saubia Fathima, Kebede H. Begna, Aref Al‐Kali, James Foran, Jeanne Palmer, Talha Badar, Mrinal M. Patnaik, Kaaren K. Reichard, Rong He, Cinthya J. Zepeda Mendoza, Mithun Shah, Attilio Orazi, Daniel A. Arber, Animesh Pardanani, Alessandro M. Vannucchi, Devendra Hiwase, Naseema Gangat, Paola Guglielmelli
-
Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re‐Evaluation of Recommended Dose Adjustments With Azole Antifungals Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-28 Jitesh D. Kawedia, Caitlin R. Rausch, Xiaoqian Liu, Wei Qiao, Courtney D. Dinardo, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Patrick Reville, Dimitrios P. Kontoyiannis, Nicholas Short, Marina Konopleva, Elias Jabbour, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia
Incorporation of the BCL-2 inhibitor, venetoclax (VEN), into the treatment paradigm of acute myelogenous leukemia (AML) has led to a dramatic improvement in outcomes for older and unfit patients, demonstrating an overall survival benefit when added to azacitidine in patients with newly diagnosed (ND) AML ≥ 75 years, or otherwise ineligible for intensive chemotherapy [1]. Posaconazole prophylaxis has
-
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-28 Michael Hallek
Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia. It typically occurs in older patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and apoptosis in clonal B-cells.
-
Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-27 Qing Wei, Shimin Hu, Sanam Loghavi, Gokce A. Toruner, Farhad Ravandi-Kashani, Zhenya Tang, Shaoying Li, Jie Xu, Naval Daver, L. Jeffrey Medeiros, Guilin Tang
Chromoanagenesis (CAG) encompasses a spectrum of catastrophic genomic events, including chromothripsis, chromoanasynthesis, and chromoplexy. We studied CAG in 410 patients with a diagnosis of acute myeloid leukemia (AML), 292 newly diagnosed (ND), and 118 refractory/relapsed, using optical genome mapping. CAG was identified by the presence of clusters (with 10 or more breakpoints) of structural abnormalities
-
Association Between Red‐Cell Transfusion in Childbirth and Long‐Term Risk of Lymphoma and Autoimmune Disease: A Swedish Nationwide Cohort Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-27 Anne Brynolf, Anna Sandström, Henrik Hjalgrim, Gustaf Edgren
Red-cell transfusions during childbirth are essential for managing significant blood loss, but may have long-term immunological implications. While immediate risks like transfusion-transmitted infections are well-documented, less understood are the potential associated risks of future lymphoma and autoimmune disease [1]. We performed a study that aimed to assess the long-term risk of developing non-Hodgkin
-
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-25 Robby Engelmann, Juan Flores-Montero, Joyce Schilperoord-Vermeulen, Matthias Ritgen, Paul J. Hengeveld, Saskia Kohlscheen, Georgiana Grigore, Rafael Fluxa Rodriguez, Quentin Lecrevisse, Jan Philippé, Neus Villamor, Paula Fernandez, Leire Burgos, Jacques J. M. van Dongen, Alberto Orfao, Anton W. Langerak, Sebastian Böttcher
Submicroscopic levels of leukemic cells that persist after treatment are commonly designated as measurable residual disease (MRD). The last decade has witnessed a growing body of evidence proving the prognostic significance of MRD for both progression-free and overall survival in chronic lymphocytic leukemia (CLL) [1, 2]. Moreover, MRD detection is now increasingly used to tailor treatment in accordance
-
Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-25 Mizuna Otsuka, Tomohiro Koga, Remi Sumiyoshi, Shoichi Fukui, Yuko Kaneko, Takayuki Shimizu, Atsushi Katsube, Shingo Yano, Yasufumi Masaki, Makoto Ide, Hajime Yoshifuji, Masayasu Kitano, Yasuharu Sato, Naoki Sawa, Hiroaki Niiro, Naoya Nakamura, David C. Fajgenbaum, Frits van Rhee, Atsushi Kawakami
Individuals diagnosed with Castleman disease (CD) and TAFRO syndrome (characterized by thrombocytopenia, anasarca, fever, bone marrow fibrosis, and organomegaly) displays a wide range of clinical symptoms, including varying patterns of lymph node enlargement, systemic inflammation, and impaired organ function. Some patients may present with both CD and TAFRO syndrome concurrently. A retrospective study
-
NOTCH1 Mutations Are Associated With Therapy‐Resistance in Patients With B‐Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-25 Emil R. Kyvsgaard, Morten Grauslund, Lene Sjø, Linea Cecilie Melchior, Trine Lønbo Grantzau, Lise Mette Rahbek Gjerdrum, Trine Trab, Lærke Sloth Andersen, Anne Ortved Gang, Marie Breinholt, Michael Boe Møller, Jacob Haaber Christensen, Thomas Stauffer Larsen, Michael Roost Clausen, Caroline H. Riley, Carsten U. Niemann, Kirsten Grønbæk, Martin Hutchings, Simon Husby
CD20 × CD3 bispecific antibodies such as glofitamab, epcoritamab, and mosunetuzumab are novel T cell engaging antibodies which have all shown convincing results and obtained FDA and EMA approval for the treatment of relapsed/refractory diffuse large B cell lymphomas (DLBCL) or follicular lymphoma (FL) with ≥ 2 prior lines of treatment [1]. However, approximately 50% of patients do not achieve remission
-
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-22 Nichola Cooper, A. J. Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F. Ypma, Vickie McDonald, Charles Percy, Milan Košťál, Isaac Goncalves, Lachezar H. Bogdanov, Terry B. Gernsheimer, Remco Diab, Mengjie Yao, Ahmed Daak, David J. Kuter
-
Combination of Biological Aging and Genetic Susceptibility Helps Identifying At‐Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-22 Zhensheng Hu, Jiatang Xu, Runnan Shen, Liling Lin, Yangfan Su, Chaoyu Xie, Guochang You, Yi Zhou, Kai Huang
Phenotypic age acceleration (PhenoAgeAccel) is a novel clinical aging indicator. This study was carried out to investigate the relationship between PhenoAgeAccel and the incidence of VTE, as well as to integrate PhenoAgeAccel with genetic susceptibility to improve risk stratification of VTE. The study included 394 041 individuals from the UK Biobank. Phenotypic age was calculated based on actual age
-
CM313 Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter, Phase 1 Dose-Escalation and Dose-Expansion Trial Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-22 Huixing Zhou, Zhongxia Huang, Baijun Fang, Hongmei Jing, Zhongjun Xia, Yuqin Song, Zhen Cai, Gang An, Ling Qin, Li Bao, Xin Li, Yuzhang Liu, Yanrong Wang, Ling Li, Wenming Chen
Multiple myeloma (MM) accounts for approximately one-tenth of all hematological malignancies. Although immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) have significantly prolonged survival of MM patients, relapses are almost inevitable [1]. Patients refractory to IMiDs and PIs have a poor prognosis, highlighting the urgency to develop new agents with target specificity in patients with
-
Erdheim‐Chester Disease With Significant Response of Large Vessel Disease to Cobimetinib Monotherapy Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-22 Nehaal Ahmed, Jithma P. Abeykoon, Angela Collie, Matthew J. Koster
Conflicts of Interest The authors declare no conflicts of interest.
-
Association Between Anticoagulant-Related Bleeding and Mortality in Patients With Solid Tumors and Cancer-Associated Venous Thromboembolism Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-21 Amir Mahmoud, Suhong Luo, Brian F. Gage, Amber Afzal, Kenneth Carson, Su-Hsin Chang, Martin Schoen, Tzu-Fei Wang, Kristen M. Sanfilippo
-
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-20 Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, Calogero Vetro, Maria Paola Martelli, Cristina Papayannidis, Ernesta Audisio, Paola Minetto, Carola Riva, Fabio Guolo, Gianluca Martini, Patrizia Zappasodi, Federico Vincenzo, Federica Gigli, Davide Griguolo, Michela Rondoni, Giulia Ciotti, Erika Borlenghi, Nadia Ciccone, Fanny Erika Palumbo, Jacopo Nanni, Daniele Mattei, Massimo Bernardi,
-
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-17 Michael Auerbach, Myles Wolf
Conflicts of Interest The authors declare no conflicts of interest.
-
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-17 Emma N. Cravo, Hannah L. Hays, Jaahnavi Badeti, Henry A. Spiller, Natalie I. Rine, Motao Zhu, Gary A. Smith
The objective of this study was to investigate the characteristics and trends of therapeutic errors in non‐healthcare facility settings associated with antithrombotic medications reported to United States Poison Centers by analyzing data from the National Poison Data System from 2000 to 2021. There were 57 288 reported therapeutic error‐related exposures involving antithrombotic medications as the
-
Clinical Validation of Optical Genome Mapping in Multiple Myeloma Without Plasma Cell Enrichment Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-17 Jung Yoon, Jung Ah Kwon, Soo‐Young Yoon
Cytogenetic alterations are important in risk stratification for multiple myeloma (MM). Translocations involving the immunoglobulin heavy chain (IGH), such as t(4;14), t(14;16), as well as del(17p) and gain(1q), are recognized as high-risk cytogenetic markers in staging systems [1]. Fluorescence in situ hybridization (FISH) is the primary method for detecting these genetic alterations. However, cytogenetic
-
Residual Cerebrovascular Morbidity Despite Treatment in Pediatric Sickle Cell Disease Highlights Opportunities for Earlier, Intensified Monitoring and Treatment Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-16 Giulia Reggiani, Beatrice Coppadoro, Maria Paola Boaro, Roberta Trapanese, Ilaria Baido, Alessandra Biffi, Federica Viaro, Alessio Pieroni, Matteo Minerva, Giovanna Barcelos, Renzo Manara, Claudia Baracchini, Raffaella Colombatti
We read with great interest the article by Casella et al. [1] which reported the results of the HU Prevent Trial. Regardless of the limitations acknowledged by the authors, Casella's study suggests that Hydroxyurea (HU) may have neuroprotective effect in very young children with sickle cell disease (SCD) and support a phase III study to encourage the early use of HU in all infants with SCD. While many
-
Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-15 Kathryn Lurain, Ramya Ramaswami, Eric Oksenhendler, David Boutboul, Alessia Dalla Pria, Lara Ulrich, Krithika Shanmugasundaram, Thomas S. Uldrick, Mark Bower, Robert Yarchoan, Laurence Gérard, Seth M. Steinberg
-
Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre‐Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-15 Ondrej Venglar, Eva Radova, David Zihala, Ivana Tvrda, Viktor Kubala, Kamila Kutejova, Ludmila Muronova, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Tereza Sevcikova, Michal Kascak, Milan Navratil, Zdenek Koristek, Roman Hajek, Tomas Jelinek
High-dose melphalan followed by autologous stem cell transplantation (ASCT) remains the standard of care for multiple myeloma (MM) patients. However, hematopoietic cell autografts are often contaminated with aberrant plasma cells (aPC) following CD34+ cell mobilization [1], making graft MRD (gMRD) assessment potentially valuable. Nevertheless, the clinical significance of gMRD was not fully leveraged
-
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo‐Gaucher Cells Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-13 Natalia Scaramellini, Marta Canzi, Elena Cassinerio, Margherita Migone De Amicis, Loredana Pettine, Bruno Fattizzo, Francesca Gaia Rossi, Giorgio Croci, Irene Motta
A 35-year-old man came to our attention for the suspicion of Gaucher disease (GD). The patient had undergone a bone marrow aspirate and biopsy because of massive splenomegaly (30 cm), severe thrombocytopenia (platelet count 30 000/mm3), and mild anemia [hemoglobin (Hb) 12.1 g/dL] observed in the emergency department, where he presented for acute abdominal pain. Bone marrow biopsy (BMB) revealed foci
-
A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-10 Chia‐Yu Wang, Emiliano Melgar‐Bermudez, Diana Welch, Kevin B. Dagbay, Seemana Bhattacharya, Evan Lema, Tyler Daman, Olivia Sierra, Radina Todorova, Papa Makhtar Drame, Rosa Grenha, Ffolliott M. Fisher, Dena Grayson, Lorena Lerner, Samuel M. Cadena, Jasbir Seehra, Jennifer Lachey
Patients with chronic inflammation are burdened with anemia of inflammation (AI), where inflammatory cytokines inhibit erythropoiesis, impede erythropoietin production, and limit iron availability by inducing the iron regulator hepcidin. High hepcidin hinders iron absorption and recycling, thereby worsening the impaired erythropoiesis by restricting iron availability. AI management is important as
-
Impact of Baseline Thrombocytopenia on Early Outcomes in Patients With Acute Venous Thromboembolism Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-10 Ramón Lecumberri, Pedro Ruiz-Artacho, Javier Trujillo-Santos, María Marcos-Jubilar, Montserrat Pérez-Pinar, Isabelle Quéré, Gisela Claver, Juan Gorostidi, Behnood Bikdeli, Manuel Monreal
Managing acute venous thromboembolism (VTE) in patients with thrombocytopenia is challenging. We used data from the RIETE registry to investigate the impact of baseline thrombocytopenia on early VTE-related outcomes, depending on the initial presentation as pulmonary embolism (PE) or isolated lower-limb deep vein thrombosis (DVT). From March 2003 to November 2022, 90 418 patients with VTE were included
-
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-09 Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, Panagiotis Malandrakis, Efstathios Kastritis, Ourania E. Tsitsilonis, Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou
This meta-analysis examined the association between minimal residual disease (MRD) negativity and survival outcomes in 15 304 patients with multiple myeloma (MM) enrolled in randomized controlled trials published until June 2, 2024. Overall, there was a significant, negative and strong association between MRD negativity odds ratios and survival hazard ratios (β_PFS = -0.20, p < 0.001, β_OS = -0.12
-
Budesonide, Added to PTCy-Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-08 Piyanuch Kongtim, Piyatida Chumnumsiriwath, Pongthep Vittayawacharin, Deepa Jeyakumar, Benjamin J. Lee, Jean Doh, Shawn P. Griffin, Richard A. Van Etten, Stefan Ciurea
-
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-07 John T. Butler, William M. Yashar, Ronan Swords
Acute myeloid leukemia (AML) is a genetically heterogeneous disease with high rates of relapse after initial treatment. Identifying measurable residual disease (MRD) following initial therapy is essential to assess response, predict patient outcomes, and identify those in need of additional intervention. Currently, MRD analysis relies on invasive, serial bone marrow (BM) biopsies, which complicate
-
Issue Information Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-07
Click on the article title to read more.
-
Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell Lymphoma Patients in Complete Remission Following First-Line Treatment Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-05 Therese Lassen, Torsten H. Nielsen, Annika von Heymann, Lene K. Nielsen, Morten K. Larsen, Anne O. Gang, Christoffer Johansen, Lars M. Pedersen
Despite advances in treatment, approximately 15% of patients with diffuse large B-cell lymphoma (DLBCL) who achieve complete remission (CR) after first-line therapy will experience a relapse. However, there is no consensus on the optimal follow-up strategies for detecting relapse after achieving CR. This population-based study, based on the Danish Lymphoma Registry (LYFO), identified a total of 1634
-
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-05 Hagop Kantarjian, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Tapan Kadia, Musa Yilmaz, Alessandra Ferrajoli, Koji Sasaki, Yesid Alvarado, Naveen Pemmaraju, Jayastu Senapati, Rebecca Garris, Farhad Ravandi, Elias Jabbour
Adding inotuzumab ozogamicin (InO) to hyper-CVAD and blinatumomab may improve outcomes in newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). Patients with newly diagnosed B-ALL received up to four cycles of hyper-CVAD followed by four cycles of blinatumomab. Beginning with patient #39, InO 0.3 mg/m2 was added on Days 1 and 8 to two cycles of high-dose
-
The Interplay Between Ophthalmic and Systemic Outcomes in Patients With Sickle Cell Disease and Concurrent Retinopathy—A Population-Based Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-04 Purna Nangia, Karen M. Wai, Adrienne W. Scott, Ehsan Rahimy, Prithvi Mruthyunjaya
Sickle cell disease (SCD) is the most common hemoglobinopathy worldwide caused by the presence of hemoglobin S or sickle hemoglobin [1]. It is estimated to affect 100 000 people in the United States and more than 3 million people worldwide [2]. Chronic and recurrent sickling, hemolysis, and endovascular inflammation results in pain and end-organ damage [3]. Patients with SCD suffer from acute and chronic
-
Clinical Characteristics and Prognosis of Pediatric Idiopathic Multicentric Castleman Disease Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-03 Yu-han Gao, Jia-feng Yao, Si-yuan Li, Yue Dang, Hao-yi Xu, Tong Zou, Jian Li, Lu Zhang, Rui Zhang
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by marked heterogeneity among patients, with severity ranging from mild to life-threatening [1]. Although cases have been documented across all age groups, the diagnosis of iMCD typically occurs in the fifth decade of life and is relatively uncommon in children [1]. A previous analysis of the ACCELERATE
-
Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-02 Jennifer E. Bruno, Christine A. Herne, Andrea M. Baran, Karl R. VanDerMeid, Paul M. Barr, Alyssa R. Williams, Sally A. Quataert, Tim R. Mosmann, Clive S. Zent, Charles C. Chu
-
Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-26 Patricia Carey, Animesh Pardanani, Patrick Starlinger, Ayalew Tefferi, Naseema Gangat
-
Unlocking Sanctuary Sites: The Efficacy of Brexucabtagene Autoleucel in Ocular B-ALL Relapse Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-24 Ludovica Calabretta, Patrizia Zappasodi, Carlo Di Biase, Cristina Picone, Elisa Roncoroni, Marianna Rossi, Antonio Bianchessi, Irene Defrancesco, Caterina Zerbi, Beatrice Ferrari, Erica Consensi, Gianluca Martini, Claudia Patricia Tobar Cabrera, Claudia Battista, Alessandro Mazzacane, Francesco Romano, Giulia Losi, Alessia Taurino, Luca Arcaini, Nicola Polverelli
Conflicts of Interest The authors declare no conflicts of interest.
-
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-24 Jayastu Senapati, Hagop M. Kantarjian, Fadi G. Haddad, Nicholas J. Short, Gautam Borthakur, Rashmi Kanagal-Shamanna, Guilin Tang, Elias Jabbour, Courtney D. DiNardo, Naval Daver, Guillermo Montalban-Bravo, Vishrut Shah, Amin Alousi, Elizabeth Shpall, Uday Popat, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
-
Heavy Metal Toxicity Secondary to Ayurvedic Medications Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-23 Bingwen Eugene Fan, Natasha Fay Anthony, Kian Guan Eric Lim, Yin Wen Lai, Ponnudurai Kuperan, Hemalatha Shanmugam
Conflicts of Interest The authors declare no conflicts of interest.
-
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-23 Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, Charles Gaulin, Evandro Bezerra, Timothy Voorhees, Madhav R. Seshadri, Ayo Falade, Alma Habib, Amy A. Ayers, Megumi Bailey, Annette Brown, Neil Bailey, Krish Patel, Charalambos B. Andreadis, Adam S. Kittai, Caron Jacobson, Joycelynne Palmer, Stephen J. Forman, Loretta Nastoupil, Lihua E. Budde
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of aggressive large B-cell lymphoma (aLBCL). Patients with transformed indolent non-Hodgkin lymphoma (tiNHL) were included in key CAR trials, but outcomes of CAR for this distinct, historically high-risk group are poorly understood. We conducted a multicenter retrospective study of 1182 patients with aLBCL receiving standard-of-care
-
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-23 Jon Salmanton-García, Francesco Marchesi, Milan Navrátil, Klára Piukovics, Maria Ilaria del Principe, Marianna Criscuolo, Yavuz M. Bilgin, Nicola S. Fracchiolla, Antonio Vena, Alessandra Romano, Iker Falces-Romero, Nicola Sgherza, Inmaculada Heras-Fernando, Monika M. Biernat, Verena Petzer, Pavel Žák, Barbora Weinbergerová, Michail Samarkos, Nurettin Erben, Jens van Praet, Alberto López-García, Jorge
-
Efficacy and Long-Term Outcomes of Eltrombopag Treatment Within 6 Months of Diagnosis in Patients With Steroid Unresponsive or Dependent Immune Thrombocytopenia Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-23 Huyen Tran, Caroline Dix, Robert Bird, Sanjeev Chunilal, Tim Brighton, John Reynolds, Simon He, Christine Mazis, Andrew Grigg
Immune thrombocytopenia (ITP) is an autoimmune disorder associated with the production of autoantibodies directed against platelet glycoprotein complexes, resulting in both accelerated destruction of platelets and a relative reduction in platelet production. In adults, the majority of the acute cases respond to initial steroid therapy, but 50% relapse by 6 months and an additional 25% relapse beyond
-
Rituximab Plus Bortezomib for Relapsed and Refractory Warm Autoimmune Hemolytic Anemia: A Prospective Phase 2 Trial Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-21 Xijuan Lin, Chen Yang, Junling Zhuang, Jian Li, Daobin Zhou, Miao Chen, Bing Han
Autoimmune hemolytic anemia (AIHA) is a complex disorder and autoantibodies optimally fight against red blood cells at 37°C in warm AIHA (wAIHA). Rituximab is the preferred second-line treatment after failure of glucocorticoids. The treatment of relapsed and refractory (RR) wAIHA is challenging, especially in emergencies with severe anemia and crossmatching incompatibility. Bortezomib induces the apoptosis
-
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-19 Nilanjan Ghosh, Toby A. Eyre, Jennifer R. Brown, Nicole Lamanna, Beenish S. Manzoor, Catherine C. Coombs, Hande H. Tuncer, Chaitra Ujjani, Lori A. Leslie, Lindsey E. Roeker, Matthew S. Davids, Joanna M. Rhodes, Alan P. Skarbnik, Wendy Sinai, Isabelle Fleury, Brian T. Hill, Nicolas Martinez-Calle, Paul M. Barr, Dureshahwar Jawaid, Nnadozie Emechebe, Laurie Pearson, Frederick Lansigan, Yun Choi, Christopher
The treatment landscape of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has evolved drastically with the introduction of targeted agents, including covalent Bruton tyrosine kinase inhibitors (cBTKis) and B-cell lymphoma 2 inhibitors (BCL2is) [1]. However, the development of cBTKi resistance (leading to disease progression) and intolerance due to adverse events limits durable
-
Risk Factors and Prognostic Markers for Posterior Reversible Encephalopathy Syndrome in Patients With Thalassemia Major After Allogeneic Hematopoietic Stem Cell Transplantation Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-19 Meiru Bu, Kemei Deng, Meiqing Wu, Lingling Shi, Yuhong Qin, Muliang Jiang, Bihong T. Chen
Posterior reversible encephalopathy syndrome (PRES) has been known as a neurological complication in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). PRES is an acute or subacute syndrome with various neurological symptoms such as headache, encephalopathy, visual disturbance and seizures [1]. Neuroimaging may show subcortical white matter vasogenic edema typically in bilateral
-
Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real-World Multicenter Retrospective Cohort Study Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-18 Jingjing Liu, Zhifa Wang, Nan Wang, Jingyao Ma, Yu Hu, Jie Ma, Lijuan Wang, Yan Liu, Juntao Ouyang, Zhenping Chen, Xiaoling Cheng, Runhui Wu
Immune thrombocytopenia (ITP) is an acquired bleeding disorder characterized by a reduced platelet count of less than 100 × 109/L, with an estimated incidence of 2–5/100 000 children per year [1]. Since 2014, the China National Medical Products Administration (NMPA) has approved five TPO-RAs for treating ITP in China. Among these, eltrombopag (ELT) and avatrombopag (AVA) are the two most evidence-based
-
Blastic Plasmocytoid Dendritic Cell Neoplasm With Pseudo‐Lymphoid Morphology Mimicking Lymphoid Malignancy Am. J. Hematol. (IF 10.1) Pub Date : 2024-12-18 Romain Ravel‐Chapuis, Gérard Buchonnet, Catherine Boutet, Francine Garnache Ottou, Anne Roggy, Florian Renosi, Olivier Matray, Victor Bobée
A 60-year-old male presented with spontaneous hematomas and cervical adenopathy. Laboratory workup revealed hemoglobin 12.3 g/dL, platelet 56 × 109/L, and leukocyte 14.7 × 109/L. The automated cell counter (Sysmex XN) reported 9% neutrophils (1.32 × 109/L) and 86% lymphocytes (12.6 × 109/L), suggestive of a lymphoproliferative disorder. Blood smear showed atypical lymphoid cells with normal size, mature